Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diaplasinin SCHEMBL4024262 | 1.00 | PLA2G4A (0.37) | PLA2G4ATLR7DYRK1AMAPTTP53 | |
| SCHEMBL14279896 | 0.88 | PPARG (0.38) | TLR7ALDH1A1SMN1; SMN2KDM4ETDP1 | |
| SCHEMBL4021345 | 0.88 | PSEN1 (0.36) | TLR7MAPTALDH1A1HPGDPSEN1 | |
| SCHEMBL14257292 | 0.88 | PLA2G4A (0.38) | PLA2G4ATLR7DYRK1AMAPTTP53 | |
| SCHEMBL4022525 | 0.88 | PTPN1 (0.37) | TLR7ALDH1A1SMN1; SMN2PSEN1PSEN2 | |
| SCHEMBL4025900 | 0.87 | ALOX5AP (0.35) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3853290 | 0.86 | ESR1 (0.40) | PLA2G4ADYRK1AALOX5AP | |
| SCHEMBL4023545 | 0.85 | TUBB4A (0.37) | PLA2G4APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4197170 | 0.83 | PSEN1 (0.52) | PLA2G4ATLR7MAPTTP53ALDH1A1 | |
| SCHEMBL4023122 | 0.82 | ALDH1A1 (0.48) | TLR7MAPTTP53ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713445-A2 | RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (TPA) FRAGMENTS AND USES THEREOF | Versiti Blood Research Institute Foundation, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| WO-2024238942-A2 | RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (TPA) FRAGMENTS AND USES THEREOF | VERSITI BLOOD RESEARCH INSTITUTE FOUNDATION, INC. (US) | 2024-11-21 | — | — | WO | claimed |
| US-20240216372-A1 | THERAPEUTICS FOR KELOIDS AND OTHER FIBROTIC DISORDERS | NATIONAL INSTITUTES OF HEALTH | 2024-07-04 | — | — | US | claimed |
| EP-4713445-A2 | RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (TPA) FRAGMENTS AND USES THEREOF | Versiti Blood Research Institute Foundation, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12383579-B2 | Materials and methods of using an inhibitor of plasminogen activation to treat anastomotic leak | THE UNIVERSITY OF CHICAGO (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4590303-A1 | VELUSETRAG FOR USE IN THE TREATMENT OF CHRONIC INTESTINAL PSEUDO-OBSTRUCTION (CIPO) | Alfasigma S.p.A. (IT) | 2025-07-30 | — | — | EP | disclosed |
| WO-2024238942-A2 | RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (TPA) FRAGMENTS AND USES THEREOF | VERSITI BLOOD RESEARCH INSTITUTE FOUNDATION, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| CN-115779092-B | Application of SERPINE1 inhibitor in preparation of medicine for promoting anti-tumor immunotherapy efficacy | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 2024-07-19 | — | — | CN | disclosed |
| US-20240216372-A1 | THERAPEUTICS FOR KELOIDS AND OTHER FIBROTIC DISORDERS | NATIONAL INSTITUTES OF HEALTH | 2024-07-04 | — | — | US | disclosed |
| WO-2024061960-A1 | VELUSETRAG FOR USE IN THE TREATMENT OF CHRONIC INTESTINAL PSEUDO-OBSTRUCTION (CIPO) | ALFASIGMA S.P.A. (IT) | 2024-03-28 | — | — | WO | disclosed |
| US-20230305023-A1 | METHODS OF TREATMENT AND DIAGNOSTIC OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH INTENSE STRESS | INST NAT SANTE RECH MED (FR) | 2023-09-28 | — | — | US | disclosed |
| EP-4171527-A1 | METHODS OF TREATMENT AND DIAGNOSTIC OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH INTENSE STRESS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-05-03 | — | — | EP | disclosed |
| CN-115779092-A | Application of SERPINE1 inhibitor in preparation of medicine for promoting antitumor immunotherapy efficacy | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 2023-03-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12383579-B2 | Materials and methods of using an inhibitor of plasminogen activation to treat anastomotic leak | PLAT, PLG, SERPINB10 | PLA2G4A 1170/4885TLR7 2821/4885DYRK1A 3170/4885 |
| US-20230305023-A1 | METHODS OF TREATMENT AND DIAGNOSTIC OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH INTENSE STRESS | SERPINE1, SERPINA6, F2RL1 | PLA2G4A 163/4885TLR7 4480/4885DYRK1A 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.